Biotech Daily

Monday August 24, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: COMPUMEDICS UP 20.5%; ARTRYA DOWN 7%**

*** CYCLOPHARM H1 REVENUE UP 14% TO $17.5m; LOSS UP 14% TO $9m**

*** PROF KATHERINE KEDZIERSKA WINS GSK $150k RESEARCH AWARD**

*** ENTROPY REQUESTS 'PHASE II TRIAL' TRADING HALT**

*** REGAL FUNDS REDUCES TO 9% OF ONCOSIL**

*** ACRUX APPOINTS DR JOLANTA AIREY CMO**

*** AVECHO APPOINTS EVE WILLIAMSON STRATEGY CONSULTANT**

*** ADHERIUM APPOINTS PRIYAMVADA RASAL, ANVI MEHTA CO-CO SECS**

MARKET REPORT

The Australian stock market was up 0.49 percent on Monday August 24, 2026, with the ASX200 up 44.2 points to 9,103.1 points.

Fourteen of the Biotech Daily Top 40 companies were up, 18 fell and eight traded unchanged. All four Big Caps were up.

Compumedics was the best, up 4.5 cents or 20.45 percent to 26.5 cents, with 379,258 shares traded.

Paradigm climbed 14.3 percent; Resonance rose 6.7 percent; Curvebeam and Medical Developments climbed more than five percent; EBR, Nova Eye, Syntara and Telix were up more than three percent; Alcidion, Cyclopharm and Optiscan rose two percent or more; Nanosonics and Pro Medicus were up one percent or more; with Aroa, Cochlear, CSL and Resmed up by less than one percent.

Artrya led the falls, down 32 cents or 6.6 percent to $4.53, with 745,948 shares traded; followed by Actinogen, down 6.5 percent to 4.3 cents, with 1.7 million shares traded.

Atomo and Prescient lost more than five percent; 4D Medical and Lumos fell more than four percent; Clarity, Imricor, Imugene and Saluda were down more than three percent; Polynovo shed 2.3 percent; Avita, Clinuvel and Emvision were down one percent or more; with Mesoblast, Neuren, Orthocell and Starpharma down less than one percent.

CYCLOPHARM

Cyclopharm says record revenue for the six months to June 30, 2026 was up 13.6 percent to $17,520,599, with net loss after tax up 14.3 percent to $8,790,748.

Cyclopharm said revenue was from sales of its Technegas lung imaging device and consumables for pulmonary embolism, and distribution of third-party products and servicing, and its increased loss reflected "continued investment in US commercial operations, a near-doubling of research and development expenditure to $570,000 as we advance our beyond [pulmonary embolism] clinical programs, and the absence of the $1,100,000 share of joint venture profit recorded in the [prior corresponding period] following the divestment of the non-core Cyclotek interest".

The company said the six months was its "fifth consecutive record half", with US Technegas revenue up 74 percent to $2.1 million, Technegas sales in other jurisdictions up 13 percent to $7.3 million and third-party distribution up four percent to $8.1 million, compared to the previous corresponding period.

Cyclopharm said it had passed peak cash burn as each US installation added recurring revenue, with monthly net cash consumption expected to fall as the base increased.

Cyclopharm managing-director James McBrayer said "the US is not a hope; it is happening … the acceleration is real, the clinical community is with us, and the commercial infrastructure is in place".

"Cyclopharm enters the second half of 2026 with every element of its US strategy delivering: full [Centres for Medicare & Medicaid Services] reimbursement, 83 revenue-generating primary sites with a contracted runway of 429 affiliated network sites, a 1,684-location engaged pipeline, marquee federal and academic reference customers, a fully deployed commercial team, and now newly published international Guidelines naming Technegas as the generally preferred ventilation agent," Mr McBrayer said.

Cyclopharm said diluted loss per share rose 5.3 percent to 7.33 cents, with net tangible assets per security down 14.8 percent to 23 cents, and it had cash and equivalents of $12,246,315 at June 30, 2026 compared to $12,410,539 at June 30, 2025.

Cyclopharm was up one cent or two percent to 50.5 cents.

GLAXOSMITHKLINE

Glaxosmithkline says it has awarded its $150,000 Award for Research Excellence to Australian immunologist Prof Katherine Kedzierska for her research on viral infections.

Glaxosmithkline said Prof Kedzierska was a laboratory head at the Peter Doherty Institute for Infection and Immunity, professor at the University of Melbourne and a fellow of the Australian Academy of Science and National Health and Medical Research Council.

The company said Prof Kedzierska's most significant breakthroughs included the discovery that elevated activity of the oleoyl-ACP hydrolase (OLAH) gene was "consistently associated with fatal outcomes across multiple respiratory illnesses".

Glaxosmithkline said Prof Kedzierska's team had found OLAH in patients with severe Covid-19 and respiratory syntactical virus suggesting the protein "may represent a common pathway underlying severe respiratory disease across multiple viruses".

The company said Prof Kedzierska was developing a blood test for patients at higher risk of facing life-threatening outcomes as well as potential therapies to interrupt the inflammatory response driven by OLAH before it becomes life-threatening.

Glaxosmithkline said the Award was "one of Australia's most prestigious and longstanding independent awards recognizing excellence in medical research".

Prof Kedzierska said the award and grant "will help us take the next step by advancing research into new ways of predicting severe disease and evaluating potential therapies".

ENTROPY NEURODYNAMICS (FORMERLY TRYPTAMINE THERAPEUTICS)

Entropy has requested a trading halt "pending a material announcement relating to a US phase II clinical trial in collaboration with Prof Robin Carhart-Harris".
Trading will resume on August 26, 2026, or on an earlier announcement.
Entropy last traded at 3.9 cents.

ONCOSIL MEDICAL

Sydney's Regal Partners Funds Management says it has reduced its substantial holding in Oncosil from 3,188,214 shares (10.39%) to 2,858,562 shares (9.25%).
Regal said it sold 329,652 shares between March 24 and August 19, 2026 for $246,497, or 74.8 cents a share.
Last year, Oncosil said it completed its 400-to-one consolidation and had 14,224,271 post-consolidation shares on issue (BD: Jun 6, 2025).
Oncosil was up one cent or 0.9 percent to $1.16.

ACRUX

Acrux says it has appointed Dr Jolanta Airey as its chief medical officer to lead the development of its female testosterone through US phase III trials and registration.
Acrux said Dr Airey had more than 20 years of experience in clinical development and medical strategy, was Cynata chief medical officer from 2021 to 2026 and had worked for CSL, Biota Pharmaceuticals and Kendle International.
The company said Dr Airey held a Doctor of Medicine from Lithuania's Vilnius University.
Acrux fell 0.1 cents or 10 percent to 0.9 cents with 2.1 million shares traded.

AVECHO BIOTECHNOLOGY

Avecho says it has appointed Eve Williamson as a strategic business development consultant to "lead the company's business development strategy".
Avecho said Ms Williamson had more than 20 years of pharmaceutical business development and commercial leadership experience and had been head of business development at CSL as well as having worked at Phebra and Hospira.
The company said Ms Williamson held a Bachelor of Pharmacy from Monash University.
Avecho fell 0.2 cents or 9.5 percent to 1.9 cents with 5.1 million shares traded.

ADHERIUM

Adherium says it has appointed Automic Group's Priyamvada Rasal and Anvi Mehta as joint company secretaries, replacing Emily Austin effective from today.
Adherium said Ms Rasal had more than 15 years of experience in company secretarial consultancies and held a Bachelor of Law and Bachelor of Commerce.
The company said Ms Mehta had more than eight years of experience in company secretarial, governance, legal and compliance roles in Australia and held a Master of international Business Management from Ireland's Trinity College Dublin.
Adherium was unchanged at a post-100-to-one-consolidation 10 cents.